Title: Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
Authors: Baron, Frédéric ×
Suciu, Stefan
Amadori, Sergio
Muus, Petra
Zwierzina, Heinz
Denzlinger, Claudio
Delforge, Michel
Thyss, Antoine
Selleslag, Dominik
Indrak, Karel
Ossenkoppele, Gert
de Witte, Theo #
Issue Date: Apr-2012
Publisher: Il Pensiero Scientifico
Series Title: Haematologica vol:97 issue:4 pages:529-533
Article number: 10.3324/haematol.2011.044347
Abstract: Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade(®)) is an anti-tumor necrosis factor alpha chimeric antibody that is used in the treatment of patients with rheumatoid arthritis or Crohn's disease. Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg vs. 5 mg/kg). The primary end point was the response rate. Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm. According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early myelodysplastic syndrome.
ISSN: 0390-6078
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Stem Cell Biology and Embryology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science